BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24962733)

  • 21. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
    Verhoef TI; Ragia G; de Boer A; Barallon R; Kolovou G; Kolovou V; Konstantinides S; Le Cessie S; Maltezos E; van der Meer FJ; Redekop WK; Remkes M; Rosendaal FR; van Schie RM; Tavridou A; Tziakas D; Wadelius M; Manolopoulos VG; Maitland-van der Zee AH;
    N Engl J Med; 2013 Dec; 369(24):2304-12. PubMed ID: 24251360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.
    Panchenko E; Kropacheva E; Dobrovolsky A; Titaeva E; Zemlyanskaya O; Trofimov D; Galkina I; Lifshits G; Vereina N; Sinitsin S; Vorobyeva N; Grehova L; Zateyshchikov D; Zotova I; Vavilova T; Sirotkina O; Grontkovskaya A
    Pharmacogenomics J; 2020 Oct; 20(5):687-694. PubMed ID: 32024944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials.
    Shi C; Yan W; Wang G; Wang F; Li Q; Lin N
    PLoS One; 2015; 10(12):e0144511. PubMed ID: 26672604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Creating an Optimal Warfarin Nomogram (CROWN) Study.
    Perlstein TS; Goldhaber SZ; Nelson K; Joshi V; Morgan TV; Lesko LJ; Lee JY; Gobburu J; Schoenfeld D; Kucherlapati R; Freeman MW; Creager MA
    Thromb Haemost; 2012 Jan; 107(1):59-68. PubMed ID: 22116191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing.
    Obeng AO; Kaszemacher T; Abul-Husn NS; Gottesman O; Vega A; Waite E; Myers K; Cho J; Bottinger EP; Ellis SB; Scott SA
    Clin Pharmacol Ther; 2016 Nov; 100(5):427-430. PubMed ID: 27393744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials.
    Tang T; Liu J; Zuo K; Cheng J; Chen L; Lu C; Han S; Xu J; Jia Z; Ye M; Pei E; Zhang X; Li M
    J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):387-94. PubMed ID: 25575537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials.
    Yang T; Zhou Y; Chen C; Lu M; Ma L; Cui Y
    J Clin Pharm Ther; 2019 Apr; 44(2):197-208. PubMed ID: 30593674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics-based warfarin dosing algorithm decreases time to stable anticoagulation and the risk of major hemorrhage: an updated meta-analysis of randomized controlled trials.
    Wang ZQ; Zhang R; Zhang PP; Liu XH; Sun J; Wang J; Feng XF; Lu QF; Li YG
    J Cardiovasc Pharmacol; 2015 Apr; 65(4):364-70. PubMed ID: 25551322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).
    Anderson JL; Horne BD; Stevens SM; Woller SC; Samuelson KM; Mansfield JW; Robinson M; Barton S; Brunisholz K; Mower CP; Huntinghouse JA; Rollo JS; Siler D; Bair TL; Knight S; Muhlestein JB; Carlquist JF
    Circulation; 2012 Apr; 125(16):1997-2005. PubMed ID: 22431865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized controlled trial of genotype-guided warfarin anticoagulation in Chinese elderly patients with nonvalvular atrial fibrillation.
    Zhu Y; Xu C; Liu J
    J Clin Pharm Ther; 2020 Dec; 45(6):1466-1473. PubMed ID: 32710457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
    Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF;
    Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial.
    Zambon CF; Pengo V; Moz S; Bozzato D; Fogar P; Padoan A; Plebani M; Groppa F; De Rosa G; Padrini R
    Eur J Clin Pharmacol; 2018 May; 74(5):571-582. PubMed ID: 29396738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials.
    Li X; Yang J; Wang X; Xu Q; Zhang Y; Yin T
    Thromb Res; 2015 Apr; 135(4):621-9. PubMed ID: 25628141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
    Arwood MJ; Deng J; Drozda K; Pugach O; Nutescu EA; Schmidt S; Duarte JD; Cavallari LH
    Clin Pharmacol Ther; 2017 May; 101(5):675-683. PubMed ID: 28032893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of Empiric and Pharmacogenetic Approaches in Assessment of Efficacy of Anticoagulant Therapy].
    Kokh NV; Slepukhina AA; Tsvetovskaya GA; Lifshits GA
    Kardiologiia; 2015; 55(4):57-60. PubMed ID: 26502504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotype-guided coumarin dosing: where are we now and where do we need to go next?
    Baranova EV; Verhoef TI; Asselbergs FW; de Boer A; Maitland-van der Zee AH
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):509-22. PubMed ID: 25595525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and Validation of a Novel Warfarin Dosing Algorithm for Korean Patients With
    Cho EH; Lee K; Yang M; Choi R; Baek SY; Sohn I; Kim JS; On YK; Bang OY; Cho HJ; Lee SY
    Ann Lab Med; 2020 May; 40(3):216-223. PubMed ID: 31858761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.